Cannabidiol Oral Solution for Rare Disease-associated Severe Epilepsy

Phase 2, open-label, single-arm trial of cannabidiol in epilepsy, sponsored by Meyer Children's Hospital IRCCS. Primary endpoints: Change in number of generalized and/or focal motor-onset seizure frequency at 24 weeks and Change in severity of generalized and/or focal motor-onset seizure frequency at 24 weeks. Started Mar 2024; status: active, not recruiting.